Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOX4 | Q9NPH5 | 8/20 | 0.51 |
| ▸ | CYBB | P04839 | 3/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.38 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.38 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.38 |
| ▸ | NMT2 | O60551 | 2/20 | 0.37 |
| ▸ | NMT1 | P30419 | 2/20 | 0.37 |
| ▸ | NOX5 | Q96PH1 | 2/20 | 0.36 |
| ▸ | NOX1 | Q9Y5S8 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | NOS3 | P29474 | 1/20 | 0.36 |
| ▸ | NOS1 | P29475 | 1/20 | 0.36 |
| ▸ | NOS2 | P35228 | 1/20 | 0.36 |
| ▸ | BCHE | P06276 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2217872 | 0.89 | NOX4 (0.48) | NOX4CYBBKDM4EBCHE | |
| SCHEMBL2216293 | 0.85 | NOX4 (0.54) | NOX4CYBBGRIN1GRIN2BNOX5 | |
| SCHEMBL2219796 | 0.85 | NOX4 (0.46) | NOX4CYBBBCHE | |
| SCHEMBL2218953 | 0.80 | NOX4 (0.58) | NOX4CYBBNOX5NOX1 | |
| SCHEMBL2216058 | 0.76 | NOX4 (0.45) | NOX4CYBBNOX5NOX1KDM4E | |
| SCHEMBL2217875 | 0.74 | NOX4 (0.51) | NOX4CYBB | |
| SCHEMBL2219561 | 0.74 | NOX4 (0.66) | NOX4CYBBNOX5NOX1 | |
| SCHEMBL2216985 | 0.73 | NOX4 (0.49) | NOX4CYBBGRIN1GRIN2B | |
| SCHEMBL2216036 | 0.72 | NOX4 (0.53) | NOX4CYBBNOX1KDM4E | |
| SCHEMBL2219120 | 0.72 | NOX4 (0.46) | NOX4CYBB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2674160-B1 | Pyrazolo pyridine derivatives as NADPH oxidase inhibitors | GENKYOTEX SA (CH) | 2015-10-28 | — | — | EP | disclosed |
| US-9012449-B2 | Pyrazolo pyridine derivatives as NADPH oxidase inhibitors | GENKYOTEX SA (CH) | 2015-04-21 | — | — | US | disclosed |
| EP-2674160-A1 | Pyrazolo pyridine derivatives as NADPH oxidase inhibitors | GenKyoTex SA (CH) | 2013-12-18 | — | — | EP | disclosed |
| US-20130143879-A1 | PYRAZOLO PYRIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS | GENKYOTEX SA (CH) | 2013-06-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130143879-A1 | PYRAZOLO PYRIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS | NOX1, NOX4, CYBB | NOX4 2/4885CYBB 3/4885MAPK1 698/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.